Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts

G Pratesi1, M Tortoreto1, C Corti1, R Giardini2 and F Zunino1

Divisions of 1Experimental Oncology B and 2Pathologic Anatomy, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Summary The therapeutic effects of intraperitoneal topotecan, a water-soluble camptothecin analogue, were investigated in two models of human ovarian carcinoma xenografted intraperitoneally into nude mice: the IGROV-1 tumour, which originated from an untreated patient, and the A2780 tumour, selected for resistance to cisplatin. In IGROV-1 tumour-bearing mice, the optimal dose (10 mg kg−1) of topotecan, given intraperitoneally every 4 days for four occasions markedly increased survival time over control mice (300 T/C%) and cured 4/9 mice, and such effects were not achieved by any of the clinically available drugs tested, i.e. cisplatin, carboplatin and doxorubicin delivered intraperitoneally according to their optimal doses and schedules. In the treatment of A2780DDP tumour-bearing mice, topotecan was very effective since, at dose levels of 6.6 and 10 mg kg−1 every 4 days for four occasions, 15/18 mice survived more than 100 days, and most of them (12/15) were found to be tumour free. The high responsiveness of this tumour to topotecan might be related to the elevated expression of the target enzyme topoisomerase I. From these results, intraperitoneal treatment with topotecan appears to be a promising approach in the therapy of refractory ovarian cancer confined to the peritoneal cavity.

Keywords: topotecan; ovarian carcinoma; local regional therapy

Ovarian cancer is an important cause of death in cancer patients, and its natural history is characterised by predominant growth of the disease in the peritoneal cavity. Thus, ovarian cancer represents a particularly good target to exploit the pharmacological advantage (i.e. high concentration of an active agent at the tumour site) of intraperitoneal (i.p.) administration of very potent cytotoxic agents characterised by a low therapeutic index or an unfavourable pharmacological profile. However, local toxicity represents a major limitation of i.p. therapy with conventional agents (e.g. doxorubicin, mitoxantrone). Thus, although the role of i.p. therapy is still a matter of debate (Ozols, 1992), selection of the appropriate drug appears to be critical for optimisation of this approach (Markman, 1986).

Camptothecins, known as DNA topoisomerase I (topo I) inhibitors (Liu, 1989), represent a new class of anti-tumour agent of particular interest because in preclinical studies they were found to be effective in the treatment of intrinsically resistant tumours (including melanoma and colon carcinoma) (Giovannella et al., 1989, 1991) and showed a broad spectrum of activity (Johnson et al., 1992). Their clinical use is still limited by systemic toxicities, including myelosuppression and gastrointestinal toxicities. In preclinical evaluation and in preliminary clinical studies, these agents were found to be devoid of local toxicity when administered by the i.p. and intramuscular routes (Giovannella et al., 1991; Houghton et al., 1992; Plaxe et al., 1993). Topotecan (10-hydroxy-9-dimethylaminomethyl-(S)-camptothecin), CPT-11 (7-ethyl-10-(4-1-piperidino)-1- peperidino-carbonyloxycamptothecin) and 9-aminocamptothecin were selected for clinical development (Schlennmyer et al., 1993).

Human ovarian carcinomas have been successfully xenografted into nude athmic mice subcutaneously (Friedlander et al., 1985; Kleine, 1986) and i.p. (Ward et al., 1987; Pratesi et al., 1990a). These models closely mimic the clinical situation since tumour growth produces ascites and intraabdominal carcinomatosis.

The aim of the study was to investigate the efficacy of i.p. topotecan, a water-soluble semisynthetic camptothecin analogue which does not require metabolic activation, against two i.p. growing ovarian carcinoma xenografts, one of which has been selected for resistance to cisplatin, the most effective drug in the clinical treatment of this tumour.
was dissolved in saline and other drugs in sterile distilled water, and all were delivered in a volume of 10 ml kg⁻¹ body weight.

Topotecan treatments were delivered i.p. every 4 days for four occasions to tumour-bearing mice, starting 3 days after tumour injection. This schedule was reported to be active in a series of human subcutaneously growing tumour xenografts (Houghton et al., 1992). For the established drugs, the maximum tolerated doses (i.e. less than or equal to lethal dose killing 10% of mice) were administered in different treatment schedules. Each experimental group included 8–9 mice, and median survival time (MST) was calculated for dead mice only. The death of mice before the first control mouse (or after it with a body weight reduction of more than 30%) was ascribed to drug toxicity. The MST of the treated mice divided by the value of the control mice × 100 was calculated and expressed as T/C%. Mice surviving for over 100 days were reported separately as long-term survivors (LTS).

Standard histological examination was carried out on diaphragm, liver, spleen, kidneys, stomach, ovaries and uterus of survivors.

Technical procedures for subcutaneous (s.c.) tumour xenografts have been reported (Pratesi et al., 1989). Growth of s.c. tumours (Table II) was followed by biweekly caliper measurement of length and width. Tumour volume (TV) was calculated in mm³ using the formula TV = width² × length/2 according to Geran et al. (1972). The effects achieved by the drug treatment were expressed as TV inhibition per cent (TVI%), which was calculated from the formula 100-(TV/C × 100), where T is the mean TV of treated tumours and C that of control tumours.

**Northern blot analysis**

Human tumours were excised from mice and cleaned free of normal tissue. Total RNA was prepared by the lithium chloride–guanidine monothiocianate method (Cathala et al., 1983) from frozen solid tumour tissue. Northern blot analysis was performed as already described (Pratesi et al., 1990b). Briefly, total RNA (20 μg) was fractionated on a formaldehyde-containing 1% agarose gel and transferred to a Hybond-N filter. Hybridisations were carried out for 20 h at 42°C with denaturated random primed topo I or γ-actin probes (Juan et al., 1988; Miwa and Kamada, 1990). The final wash of the filter was performed at 55°C in 0.5 × SSPE (3.6 M sodium chloride, 0.2 M sodium phosphate pH 7.7, 0.02 M disodium EDTA), and autoradiography was carried out at −70°C on Amersham MP film. Topo I gene expression was quantified using a Phosphorlmager (Molecular Dynamics, Sunnyvale, CA, USA) by dividing the radioactivity of the transcript by that of the γ-actin gene.

**Results**

The effect of i.p. topotecan on survival time of IGROV-1 tumour-bearing mice is shown in Figure 1. Topotecan showed a dose-dependent effect, since 10 mg kg⁻¹ was the optimal dose when given every 4 days for four occasions, and 15 mg kg⁻¹ was toxic (five of nine mice died before the first control mouse). Table I compares the efficacy against the i.p. growing IGROV-1 tumour of anti-tumour drugs employed in clinical therapy of ovarian carcinoma. A direct comparison of drug efficacy was carried out between doxorubicin and topotecan and a statistically significant difference in mice survival time was achieved (doxorubicin vs topotecan 10 mg kg⁻¹, P<0.001 by two-sided Mann–Whitney rank test). The results reported for the other drugs were obtained from different experiments in which each drug was delivered i.p. at its optimal dose according to different treatment schedules. Topotecan at its optimal dose was the most effective agent in the treatment of the IGROV-1 tumour, in terms of an increase in survival time as well as the number of long-term survivors. When sacrificed at the end of the experiment, mice treated with topotecan presented few tumour nodules in the peritoneal cavity and no ascites.

Figure 2 presents the effects of topotecan and cisplatin on the survival time of A2780DDP tumour-bearing mice. The drugs were delivered according to the same treatment schedule (every 4 days for four occasions). As expected, cisplatin produced only a marginal increase in mouse MST (T/C% = 162) without inducing long-term survival. In contrast, all mice but one survived over 100 days in the group treated with the optimal dose of topotecan (10 mg kg⁻¹) and all but two in the group treated with the lower dose (P<0.001 for both topotecan doses vs cisplatin by two-sided Mann–Whitney rank test). At necropsy, 3 of the 15 sur-

---

**Table I** Efficacy of local regional treatment with anti-tumour drugs on the IGROV-1 tumour xenograft growing i.p.

| Drug      | Dose (mg kg⁻¹) | Days of treatment | No. of deaths | T/C%* | LTS   |
|-----------|----------------|-------------------|---------------|-------|-------|
| Topotecan | 6.6            | 3, 7, 11, 15      | 0/9           | 260   | 0/9   |
|           | 10             | 3, 7, 11, 15      | 0/9           | 300   | 4/9   |
|           | 15             | 3, 7, 11, 15      | 5/9           | 53    | 1/9   |
| Doxorubicin| 5              | 3, 7, 11, 15      | 1/9           | 233   | 0/9   |
|           | 7.5            | 8, 15, 22         | 0/16          | 205−228<sup>b</sup> | 0/16 |
| Cisplatin | 4              | 3, 7, 11          | 0/19          | 185−200<sup>b</sup> | 2/19 |
|           | 4              | 7, 11, 15         | 0/9           | 140   | 1/9   |
|           | 6              | 8, 15, 22         | 5/55          | 170−250<sup>b</sup> | 6/55 |
| Carboplatin| 60             | 7, 11, 15         | 1/9           | 95    | 1/9   |

*Calculated on dead mice only. <sup>b</sup>Results from two experiments. <sup>c</sup>Range of values in six experiments.
vivors presented few tumour nodules in the peritoneal cavity. In the other 12 surviving mice, histological examination of abdominal organs (spleen, liver, diaphragm, stomach, kidneys, ovaries and uterus) showed no evidence of disease.

In order to demonstrate the drug resistance of the A2780/DDP tumour line, cisplatin activity was compared in s.c. growing A2780 and A2780/DDP tumours, because the parent cell line only occasionally grows in the ascitic form after i.p. transplantation and could not be established as an i.p. tumour model. Although the two tumours had a similar growth rate in the nude mouse (doubling time around 4 days), the A2780/DDP tumour was resistant to intravenous treatment with cisplatin (days 3, 10 and 17), which, on the contrary, inhibited tumour growth of the parent A2780 tumour even when delivered to advanced tumours (days 14, 21 and 28) (Table II).

Figure 2 shows the levels of topoisomerase I expression in IGROV-1 and A2780 parent tumour lines and their cisplatin-resistant variant. The A2780/DDP tumour line, which was highly sensitive to topotecan, had the highest enzyme level.

**Discussion**

Local regional treatment with topotecan of two human ovarian carcinomas growing i.p. in nude mice resulted in a marked increase in survival time and a high number of survivors, most of which had no evidence of tumour in the abdominal cavity even when inspected histologically. Topotecan was the most active compound against the IGROV-1 tumour compared with established anti-tumour drugs employed in the clinical therapy of ovarian carcinomas. The anti-tumour activity of local regional topotecan treatment could not be assessed in the IGROV-DDP tumour line, because these cells in the nude mice do not grow as ascites but only subcutaneously. The results in IGROV-1 tumour support the opportunity of clinical phase II trials with i.p. topotecan in patients with ovarian carcinoma. Reduction in ascites has been reported in a phase I trial of i.p. topotecan (Plake et al., 1993).

Interestingly, topotecan was impressively active against the A2780 tumour made resistant to cisplatin. As already suggested by a phase I clinical study (Rowinsky et al., 1992), this finding indicates that the compound should be evaluated in clinical trials for recurrent ovarian carcinoma refractory to cisplatin. Northern blot analysis indicated that the A2780/DDP tumour line has a very high level of top I expression. It is therefore likely that the impressive anti-tumour efficacy of topotecan against this tumour was related to the level of expression of the primary target of the drug (Liu, 1989). This interpretation is supported by the fact that in camptothecin-resistant cell lines a reduction in the amount of DNA topo I (Kanzawa et al., 1990) as well as a qualitative alteration of the enzyme (Tanzawa and Pommier, 1992) have been reported. Whether this cisplatin-resistant tumour exhibits a true collateral sensitivity to topotecan compared with the parent A2780 tumour remains to be determined in the s.c. growing tumours. In fact, a comparable local regional treatment of parent and cisplatin-resistant tumours is not possible, since the former grew poorly after i.p. inoculation in the nude mice. Evidence of this hypothesis has been reported in a human cisplatin-resistant bladder cancer cell line (Kotoh et al., 1994). An increased topo I expression in cisplatin-resistant cells is not surprising, since the enzyme may be involved in repairing DNA damage (Slichenmyer et al., 1993). However, an overexpression of topo I following development of resistance to cisplatin could not be regarded as a general phenomenon, and it was not found in the IGROV-DDP tumour (Figure 3). Relevant to this point is the observation that there was no difference in median topo I activity in untreated and platinum-treated patients (van der Zee et al., 1991). Taken together, these observations support the interest in the use of topo I inhibitors for platinum-preferted ovarian cancer.

An additional interest for the local regional use of camptotheceins derives from their behaviour in aqueous solutions (Underberg et al., 1990). These agents are known to undergo a pH-dependent interconversion between active lactone and inactive carboxylate forms. It is evident that i.p. administration allows a more rapid access than systemic therapy of the active drug form to the cellular target, thereby preventing the expected interconversion at the plasma level.

In summary, i.p. treatment with topotecan appears to be feasible since the drug is well tolerated, with no evidence of

---

**Table II** Cisplatin (6 mg kg⁻¹ per treatment, i.v.) efficacy against the s.c. human ovarian A2780 xenograft and its cisplatin-resistant variant

| Tumour line | Days | Treatment | Tumour volume (mm³)* | TVP%* |
|-------------|------|-----------|----------------------|-------|
| A2780       | 14, 21, 28 | 500       | 65                   |
| A2780/DDP   | 3, 10, 17  | 50        | 30                   |

*Mean tumour volume at the first day of treatment. †Tumour volume inhibition per cent 1 week after the last treatment.
local tissue damage (i.e. typical local toxicity of most cytotoxic agents). Moreover, from this preclinical study, i.p. topotecan seems to be a very promising approach for future attempts to improve treatment of ovarian cancer by means of the peritoneal cavity, as a consolidation therapy after a cisplatin-based treatment or as a second-line therapy for refractory disease.

References

BEHRENS BC, HAMILTON TC, MASUDA H, GROTZINGER KR, WHANG-PENG J, LOUIE KG, KNUTSEN T, MCKOY WM, YOUNG RC AND OZOLS RF. (1987). Characterization of a cis-diaminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res., 47, 601-605.

CATHALA G, SAVOURE JF, MENDEZ B, WEST BL, KARIN M, MARTIAL JA AND BAXTER JD. (1983). A method for isolation of intact, translationally active ribonuclease A. DNA, 2, 329-335.

FRIEDLANDER ML, RUSSELL P, TAYLOR JW AND TATTERSALL MH. (1985). Ovarian tumor xenografts in the study of the biology of human epithelial ovarian cancer. Br. J. Cancer, 51, 319-333.

GERAN RJ, GREENBERG NH, MACDONALD MM, SCHUMACHER AM AND ARBOUR BI. (1972). Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep., 3, 1-88.

GIOVANELLA BC, STEHLIN JS, WALL ME, WANI MC, NICHOLAS AW, LIU LF, SILBER R AND POTMESIL M. (1989). DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science, 246, 1046-1048.

GIOVANELLA BC, HINZ HR, KOZIELSKI AJ, STEHLIN JS, SILBER R AND POTMESIL M. (1991). Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20(S)-camptothecin. Cancer Res., 51, 3052-3055.

HOUGHTON PJ, CHESIRE PJ, MYERS L, STEWART CF, SYNOLD TW AND HOUGHTON JA. (1992). Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 31, 229-239.

JOHNSON RK, MCCABE FL, GALLAGHER G, WOOD J, GALEF J AND HERTZBERG RP. (1992). Comparative efficacy of topotecan, irinotecan, camptothein and 9-aminoacamptothecin in preclinical tumor models (abstract 105). 7th NCI-EORTC Symposium, Amsterdam.

JUAN CC, HWANG J, LIU AA, WHANG-PENG J, KNUTSEN T, HUEBNER K, CROCE CM, ZHANG H, WANG JC AND LIU LF. (1988). Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. Proc. Natl Acad. Sci. USA, 85, 8910-8913.

KANZAWA F, SUGIMOTO Y, MINATO K, KASAHARA K, BUNGU M, NAGAKAWA K, FUJIIWARA Y, LIU LF AND SAIDO N. (1990). Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res., 50, 5919-5924.

KLEINE W (1986). Growth of malignant gynecological tumors xenotransplanted into thymus aplastic nu/nu mice. Gynecol. Oncol., 24, 288-295.

KOTOH S, NAITO S, YOKOMIZO A, KUMAZAWA J, ASAKUNO K, KOHNO K AND KUWANO M. (1994). Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res., 54, 3248-3252.

Acknowledgements

The authors wish to thank Ms L Zanesi for editorial assistance and Mrs I Dal Bo for Northern blot analysis. This work was partially supported by the Associazione Italiana per la Ricerca sul Cancro, by the Consiglio Nazionale delle Ricerche (Finalized Project 'Applicazioni Cliniche della Ricerca Oncologica'), and by the Ministero della Sanita.

LIU LF. (1989). DNA topoisomerase poisons as antimutant drugs. Annu. Rev. Biochem., 58, 351-375.

MARKMAN M. (1986). Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat. Rev., 13, 219-242.

MAW T AND KAMADA S. (1990). The nucleotide sequence of a human smooth muscle (enteric type) y-actin cDNA. Nucleic Acids Res., 18, 4263.

OZOLS RF. (1992). Intraperitoneal salvage chemotherapy in ovarian cancer: who is left to treat? Gynecol. Oncol., 45, 1-2.

PLAXE S, CHRISTEN R, O'QUIGLEY J, BRAZY P, FREDDO J, MCCLAY E, HEATH D AND HOWELL S. (1993). Phase I trial of intraperitoneal topotecan. Proc. Am. Soc. Clin. Oncol., 12, abstr. 360.

PRATESI G, MANZOTTI C, TORTORETO M, PROSPERI E AND ZUNINO F. (1989). Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts. Tumori, 75, 60-65.

PRATESI G, TORTORETO M AND ZUNINO F. (1990a). Increased effect of doxorubicin linked to pyran copolymer in the intracavitary treatment of a human ovarian carcinoma in nude mice. Reg. Cancer Treat., 3, 40-43.

PRATESI G, CAPRANICO G, BINASCHI M, DE ISABELLA P, PILOTTO S, SUPINO R AND ZUNINO F. (1990b). Relationships among tumor responsiveness, cell sensitivity, doxorubicin cellular pharmacokinetics and drug-induced DNA alterations in two human small-cell lung cancer xenografts. Int. J. Cancer, 46, 669-674.

ROWINSKY ES, GROCHOW LB, HENDRICKS CB, ETTINGER DS, FORASTIERE AA, HUROWITZ LA, MCGUIRE WP, SARTORIUS SE, LUBJEKO BG, KAUFMANN SH AND DONOHOWER RC. (1992a). Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol., 10, 647-656.

SLICHERNYER WJ, ROWINSKY EK, DONOHOWER RC AND KAUFMANN SH. (1993). The current status of camptothecin analogues as antimutator agents. J. Natl Cancer Inst., 85, 271-291.

TANIZAWA A AND POMMIER Y. (1992). Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res., 52, 1848-1854.

UNDERBERG WJ, GOOSEN RMJ, SMITH BR AND BEIJENH JH. (1990). Equilibrium kinetics of the new experimental antimutator compound SKF 104664A in aqueous solution. J. Pharm. Biomed. Anal., 8, 681-683.

VAN DER ZEE AG, HOLLEMA H, DE JONG S, BOONSTRA H, GOUW A, WILLEMSE PHB, ZUIJLSTRA JG AND DE VRIES EG. (1991). P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum cyclophosphamide chemotherapy. Cancer Res., 51, 5915-5920.

WARD BG, WALLACE K, SHEPERD JH AND BALKWILL FR. (1987). Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res., 47, 2662-2667.